WSJ : U.S. Junk-Bond Storm: Picking Through the Wreckage

U.S. Junk-Bond Storm: Picking Through the Wreckage

The high-yield bond selloff is more nuanced than it at first appears

The U.S. high-yield bond market has come to represent the sum of all fears for investors. A poisonous combination of misallocated capital, restricted liquidity and declining commodities is hammering returns. But under the hood, the state of the market is more nuanced.

December has made an already rough year much worse. At the end of November, U.S. “junk” bonds had lost 2% this year, according to Barclays index data; by Monday’s close the market was down 5.8%.

The energy and metals and mining sectors unsurprisingly are bearing the brunt, down 21.6% and 25.4% respectively. Other sectors are doing much better by comparison. Consumer cyclical bonds are still in positive territory, albeit only just, up 0.1%; noncyclical consumer bonds are down just 0.3%. Unfortunately for the high-yield market as a whole, energy and mining companies carry a big weight: excluding financial-sector companies from the index, they account for 23% of the debt outstanding.

The swing in oil prices to a seven-year low and the decline in other commodities is driving divergence in the market. It is pushing up risk premiums across the board; that will hit both stronger and weaker companies. But it is also affecting the distribution of risk. Lower oil and commodity prices should be helpful for consumers, although the effect may take time to be felt. That is why consumer-facing companies are holding up well. The high-yield market as a whole isn’t in meltdown.

Indeed, the market has done what it has always done: provide capital to riskier companies and then sort the winners from the losers. The extended period of ultralow interest rates encouraged both companies to lever up and investors to take risk; the inevitable result is that capital has been misallocated. The biggest damage is in the riskiest credits: while double-B rated bonds have lost 2.3%, single-B bonds are down 6.3% and triple-C 13%.

The problem layered on top of that, however, is more complex: constraints around liquidity, in part due to regulation aimed at making the financial system safer, in part due to fund structures with an inbuilt liquidity mismatch. The risk is that funds facing pressure may be tempted to sell what is easiest—which is likely to be better-performing bonds—rather than the market laggards they really need to get rid of. For other investors, that offers a potential opportunity.

The twists and turns of the high-yield market now need to be watched closely. If higher-rated, stronger companies from sectors outside the oil and commodities complex were to face difficulty in raising cash, then the risk is of a wider credit crunch. At least not many companies will be trying to do so in the rest of December. January will be the real test.

>>> US Gapping Up

Gapping up
In reaction to strong earnings/guidance
: APDN +13.3%, FCEL +8.2%, ARWR +5.3%

M&A news: IRC +5.6% (agrees to be acquired by DRA Advisors funds, for $10.60 per share in cash), ICPT +4.2% (M&A speculation discussed in UK Daily Mail ), SYT +1.3% (ChemChina mulling a revised proposal to acquire Syngenta, according to Bloomberg)

Select Brazil related names showing strength: GGB +4.9%, CIG +4.7%, ENB +3.6%, SBS +3%, PBR +2.4%

Select metals/mining stocks trading higher: VALE +5.6%, AU +5.4%, MT +4.3%, RIO +1.7%, BBL +1.6%, ABX +1.4%, FCX +1.2%, AA +1.1%

Select oil/gas related names showing strength: UPL +7.9%, SDRL +2.3%, APC +1.7%, RDS.A +1.5%, TOT +1.5%, E +1.4%, BP +0.8%

Other news: KTOV +40.6% (announces that the Phase III clinical trial for KIT-302 successfully met the primary efficacy endpoint of the trial protocol as approved by the FDA), LL +26% (Whitney Tilson announced he has covered his short), UTSI +7.9% (Shanghai Phicomm Communication disclosed 31.7% active stake, stated interest in acquiring control of UTSI), WGBS +7% (Signed collaboration agreement with the Luxembourg Institute of Health), VRX +4.9% (issues response to Bloomberg article about its director Norma Provencio; also confirms new U.S. fulfillment agreements with Walgreens (WBA), along with additional participating independent pharmacies), SIRI +3.5% (attributed to new 5-year contract with Howard Stern), SNY +3.3% (Sanofi-Aventis and Boehringer Ingelheim enter asset swap negotiations; expected to be business EPS neutral in 2017 and accretive in subsequent years), NWL +3.2% (favorable commentary on Monday's Mad Money), AINV +2.8% (approves a new $50 mln stock repurchase plan ), QCOM +2.3% (believes current structure best positions itself following comprehensive review; raises Q1 EPS Guidance), MNOV +2% (Received notice of allowance for a new patent from the Chinese Patent Office which covers MN-029 (denibulin) di-hydrochloride), DIS +1.5% (may be attributed to increased buzz over Star Wars movie released this week), BA +1.4% ( raises share repurchase program to $14 bln and increased 20% to $1.09 per share), ALV +1.1% (EU New Car Reg's +13.2%), PFE +1% (increases quarterly dividend to $0.30/share from $0.28/share)

Analyst comments: TSEM
+5% (initiated with an Outperform at Oppenheimer), ECA +3.2% (upgraded to Buy from Hold at Jefferies), SYMC +2.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley), AIG +2.4% (upgraded to Outperform from Mkt Perform at Keefe Bruyette), FEYE +2.3% (initiated with a Buy at Evercore ISI ), COH +2.3% (upgraded to Outperform from Market Perform at Cowen ), AMGN +2.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley ), V +2% (added to Conviction Buy List at Goldman), BHP +1.5% (upgraded to Outperform from Neutral at Credit Suisse), PNRA +1.5% (upgraded to Neutral at Longbow), WPX +1.2% ( initiated with a Buy at Sun Trust Rbsn Humphrey), TXN +0.8% (upgraded to Outperform from Perform at Oppenheimer)

>>> Intercept Pharmaceuticals hires JPMorgan to examine bid approaches - report

Intercept Pharmaceuticals hires JPMorgan to examine bid approaches 

Intercept Pharmaceuticals (Nasdaq:ICPT), the New York-based drug developer, has engaged JPMorgan to analyse a number of takeover approaches, a market source cited in a Daily Mail report said. The market report named Ireland-headquartered Shire (LON:SHP) and UK-based GlaxoSmithKline (LON:GSK) as prospective bidders for Intercept, as well as suggesting unspecified American and Swiss companies will bid.

Shire refused to comment, the report said, noting that although Shire is attempting to acquire Illinois-based Baxalta (NYSE:BXLT) with a rumoured soon-to-be-increased GBP 19.8bn (USD 30bn) offer, Chief Executive Flemming Ornskov two months ago said Shire is also considering smaller buys.

>>> Enel/EGP independent advisor draws up share exchange ratio for merger (trans

Enel/EGP independent advisor draws up share exchange ratio for merger

KPMG, the independent advisor appointed by Enel [BIT:ENEL] and Enel Green Power [BIT:EGPW] (EGP) has recommended a share exchange ratio for the merger between the two groups, Italian language daily Milano Finanza reported.

The article cited the KPMG study and said the share exchange ratio is 0.486 newly issued Enel shares for one share in EPG. The study also noted that the merger with EGP will boost Enel's value by EUR 8.5bn, the article added.

The report said that Enel intends to issue up 770,588,712 shares to delist and merge its subsidiary EGP.

Milano Finanza daily edition

>>> Nokia could sell its patent portfolio at a right price; unlikely to make any

Nokia could sell its patent portfolio at a right price; unlikely to make any large deals - report (translated)
Nokia, the Finnish network equipment company, could sell its patent portfolio at a right price but is unlikely to make any large deals, according to Arvopaperi. The Finnish-language piece cited Tommi Saukkoriipi, the fund manager from SEB bank who was commenting on the regulatory approval of the merger between Nokia and the French Alcatel Lucent.

The piece wrote that the new Nokia is beginning to emerge and that it is possible Nokia could sell its patent portfolio. Saukkoriipi said that everything depends on the price. Nokia managed to sell its handsets at a favourable price as it did with the mapping services.

He also said that it looks unlikely that Nokia will make any large M&A deals since 90% of the market is already consolidated. Nokia could give out larger dividends to its shareholders instead, he added.

Arvopaperi

>>> Circle Oil considers debt restructuring and/or equity raise by end of 1Q16

Circle Oil considers debt restructuring and/or equity raise by end of 1Q16
S
On 29 September 2015 Circle Oil [LON:COP] announced its interim financial results, noting that it had reached agreement in principle with International Finance Corporation ('IFC') to extend its Reserve Based Lending (' RBL') facility by one year to June 2019.

Since that date, discussions have continued with a view to finalising the relevant documentation with IFC. However to date, although progress is being made, the process has not progressed as quickly as envisaged.

Despite Circle's low cost operations, trading remains very challenging due to a further weakening of global oil prices, varying production levels in NW Gemsa and the impact of macro events on payments from EGPC. As a result, and in conjunction with both the RBL extension and the December 2015 redetermination, discussions are ongoing regarding the borrowing base of the RBL facility under which USD 57.5m is currently drawn.

Following the redetermination the Company expect the borrowing base to be reduced and as a result there will be a moderate shortfall, although both parties are actively engaged in constructive dialogue to find a solution.
In light of the above, Circle is considering a number of options including a debt restructuring and/or an equity raise to right-size the balance sheet and ensure that the Company has sufficient cash flows to fund operations. The Board is working towards implementing any such transaction(s) by the end of the first quarter of 2016.

A further update will be provided in due course.